

Protocol for Raised Ca 125 in POSTMENOPAUSAL WOMEN Referred into / or seen in Secondary Care

INITIATED BY: Cwm Taf Morgannwg University Health Board Obstetric and Gynaecology Directorate

- APPROVED BY: Gynaecology forum
- DATE APPROVED: January 2022
- VERSION: One
- **OPERATIONAL DATE:** January 2022
- **DATE FOR REVIEW:** 3 years from date of approval or if any legislative or operational changes require
- **DISTRIBUTION:** Medical and nursing staff at Cwm Taf University Health Board. Via Wisdom

FREEDOM OF INFORMATION STATUS: Open

Guidelines Definition

Clinical guidelines are systemically developed statements that assist clinicians and patients in making decisions about appropriate treatments for specific conditions.

They allow deviation from a prescribed pathway according to the individual circumstances and where reasons can be clearly demonstrated and documented.

Minor Amendments


If a minor change is required to the document, which does not require a full review please identify the change below and update the version number.

Type of	Why change	Page	Date of	Version	Name of	
change	made	number	change	1 to 1.1	responsible	
					person	
					Mr Sea	
					Watermeyer	

CONTENTS

G	Guidelines Definition	2
M	Minor Amendments	2
	Protocol for raised CA125	
	Introduction	
3.	Indications for referral	5
4.	Causes for raised CA125	5
5.	References	6

Protocol for Raised Ca 125 in POSTMENOPAUSAL WOMEN Referred into / or seen in Secondary Care



When serum CA-125 levels are raised, serial monitoring of CA-125 may be helpful as rapidly rising levels are more likely to be associated with malignancy than high levels which remain static.

Addendum:

Guideline for the management of raised serum CA 125 levels with normal pelvic ultrasound findings in Primary Care

Introduction:

Serum CA 125 levels are being increasingly checked in women of all ages in the primary care as per NICE guidelines (CG122). If the CA 125 level is raised (> 35U/L), an ultrasound scan (USS) is arranged by the GP in the primary care which confirms presence or absence of pathology which would explain the raised CA 125 levels. There is a fair number of patients being referred to the gynaecology department with raised CA 125 levels with a normal ultrasound scan of the pelvis with normal ovaries.

Indication to carry out CA 125 in primary care (CG 122):

Women (especially if 50 or over) presenting with one or more of the following symptoms on a persistent (at least 1 month) or frequent (12 times per month) basis:

- □ persistent abdominal distension (women often refer to this as 'bloating')
- □ feeling full (early satiety) and/or loss of appetite
- □ pelvic or abdominal pain
- □ increased urinary urgency and/or frequency
- unexplained weight loss
- unexplained fatigue
- unexplained changes in bowel habit (for example, constipation or diarrhoea)
- □ symptoms that suggest irritable bowel syndrome if the woman is 50 years or over

If serum CA-125 is 35 U/ml or greater, an ultrasound scan of the abdomen and pelvis should be arranged.

Causes for Raised CA 125 levels: Table 1

Benign conditions causing raised CA125

- **Physiological conditions:** ovulation, pregnancy, menstruation
- Benign gynaecological conditions: PID, endometriosis, benign ovarian cysts, fibroids
- Autoimmune disease: Sjogrens syndrome, polyarteritis nodosa, SLE sarcoidosis
- GI conditions: colitis, diverticulitis
- Liver conditions: chronic active hepatitis, cirrhosis
- **Other:** heart failure, pericarditis, pancreatitis, renal disease, recent surgery, ascites, pleural effusion

Malignant conditions causing raised CA125

- Gynaecological malignancy:
 ovarian, cervical, endometrial cancers
- Other malignant conditions: breast, lung, bowel, pancreatic cancer (any site involving pleural, pericardial and peritoneal surfaces), sometimes in non-Hodgkin's lymphoma,

Comment:

CA 125 has poor sensitivity and specificity for detection of ovarian cancer. This is more so in premenopausal women. There is evidence that even CA 125 levels of 200 are likely to be because of benign conditions in premenopausal women. The only role where the CA 125 test has proven utility is for monitoring ovarian cancer and for a preoperative test in patients with an ovarian mass.

In the presence of a normal pelvic ultrasound, if a serum CA-125 assay is raised more than 35 units/ml, further appropriate investigations need to be considered to exclude/treat the common differential diagnoses (see Table 1). When serum CA-125 levels are raised, serial monitoring of CA-125 may be helpful as rapidly rising levels are more likely to be associated with malignancy than high levels which remain static.

99% of healthy women have values less than 35. Levels above 35 units are certainly seen in healthy women, but beyond the cut-off point of 35, the higher the value, the more likely there is trouble somewhere in the body.

References:

American College of Obstetricians and Gynecologists. Management of adnexal masses. ACOG Practice Bulletin No. 83. Washington DC: ACOG; 2007.

RCOG, Royal College of Obstetricians and Gynaecologists. Management of Suspected Ovarian Masses in Premenopausal Women. Guideline no. 62. 2011.

RCOG, Royal College of Obstetricians and Gynaecologists. Ovarian cysts in postmenopausal women. Guideline no. 34. 2016.

National Institute for Health and Clinical Excellence. *Ovarian cancer: The recognition and initial management of ovarian cancer*. NICE clinical guideline 122. London: NICE; 2011.